Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
VTViatris Inc. logo

Viatris Inc. (VTRS)

NASDAQ Global Select · Currency in USD
$18.00 ▼ -0.48 (-2.60%)
At close: Oct 23, 4:00 PM ET. Market closed.
$18.17 ▲ +0.17 (+0.94%)
Pre-market: Oct 26, 7:04 AM ET

Summary

Previous Close
$18.48
Open
$18.33
Day's Range
$17.86 – $18.38
52 Week Range
$9.92 – $18.75
Volume
7,217,787
Avg. Volume
9,517,482
Market Cap
$20.67B
Beta (5Y Monthly)
0.86
PE Ratio (TTM)
--
EPS (TTM)
-$0.35
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
$0.48 (2.67%)
Ex-Dividend Date
Aug 21, 2026
1y Target Est
$22.17

Profile: Viatris Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
30,000
CEO
Scott Andrew Smith

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.64 · Revenue est. $3.79B
DateEst.Actual
Aug 6, 2026$0.60$0.69Beat
May 7, 2026$0.50$0.59Beat
Feb 26, 2026$0.53$0.57Beat
Nov 6, 2025$0.62$0.67Beat
Aug 7, 2025$0.56$0.62Beat
May 8, 2025$0.49$0.50Beat

Analyst view

Consensus price target
$22.17 ▲ +23.2%
Range $20.00 – $26.00
Rating: Hold
Buy 38% · Hold 54% · Sell 8%

Get free alerts on VTRS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.